GlassScriptPhysician profile
Amber Allan
NPI 1285331454
$1,420.88
in general payments reported to CMS, 2019-2025
14 companies · $890 in 2025
The $890 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $107 · 2024: $424 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,420.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $364.51 | 2023-2025 | Airsupra |
| Actelion Pharmaceuticals US, INC. | $202.93 | 2024-2025 | Uptravi, Opsumit |
| Dexcom, INC. | $184.16 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Medtronic, INC. | $145.62 | 2024 | Interstim |
| Glaxosmithkline, LLC. | $136.46 | 2025 | Trelegy Ellipta |
| Hologic Sales and Service, LLC | $130.90 | 2024 | Aptima, Affirm Prone Biopsy System |
| Abbott Laboratories | $130.00 | 2025 | Eterna |
| Novo Nordisk INC | $23.29 | 2025 | Ozempic |
| Lilly USA, LLC | $22.35 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.64 | 2025 | Jardiance |
| Pfizer INC. | $16.85 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $16.01 | 2025 | Rexulti |
| Exact Sciences Corporation | $14.96 | 2025 | The Cologuard Plus Collection Kit |
| Alkermes, INC. | $14.20 | 2025 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Allan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.